|Bid||13.32 x 2200|
|Ask||13.70 x 3000|
|Day's range||13.61 - 13.67|
|52-week range||4.41 - 13.80|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2020 - 03 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.96|
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of AMAG Pharmaceuticals, Inc. (NasdaqGS: AMAG) to Covis Group S.à.r.l. Under the terms of the proposed transaction, shareholders of AMAG will receive only $13.75 in cash for each share of AMAG that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) to Covis Group S.à r.l. ("Covis") for $13.75 per share in cash is fair to AMAG shareholders. On behalf of AMAG shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.